As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of FibroBiologics, Inc. The largest reported stake is Armistice Capital, LLC's, at 9.99%. 4 filings are on record since July 17, 2025 (Schedule 13G, August 14, 2026).
Sell to companies like FibroBiologics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Hamid Khoja · Sole voting: 630,009 · Shared voting: 0 · Sole dispositive: 630,009 · Shared dispositive: 0 · SCHEDULE 13D, 2026-09-17
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 738,977 · Sole dispositive: 0 · Shared dispositive: 738,977 · SCHEDULE 13G, 2026-08-14
- · Holder: Lind Global Fund III LP · Percent: 4.99% · SCHEDULE 13G
- · Holder: BlackRock, Inc. · Percent: 2% · SCHEDULE 13G/A
FibroBiologics, Inc. has 4 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 738,977 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| 7.5% | 630,009 | SCHEDULE 13D, 2026-09-17 | 2026-09-15 | |
| Lind Global Fund III LP | 4.99% | 230,234 | SCHEDULE 13G, 2026-04-09 | 2026-04-02 |
| BlackRock, Inc. | 2% | 750,898 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
Holding shares or following this stake? See who's behind FibroBiologics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on FibroBiologics, Inc. and the records around it.
FibroBiologics, Inc. elsewhere on the record
- Company profile and every filing Oct 2026
- Form D filing Oct 2026
- Form D filing Sep 2026
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch FibroBiologics, Inc.
Get an email when FibroBiologics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on FibroBiologics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on FibroBiologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on FibroBiologics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 0 | 738,977 | 0 | 738,977 | SCHEDULE 13G, 2026-08-14 |
| Steven Boyd | 0 | 738,977 | 0 | 738,977 | SCHEDULE 13G, 2026-08-14 |
| Hamid Khoja | 630,009 | 0 | 630,009 | 0 | SCHEDULE 13D, 2026-09-17 |
The latest filing identifies FibroBiologics, Inc. by CUSIP 31573L204 and gives its principal executive office as 9350 Kirby Drive, Suite 300, Houston, TX 77054 (SCHEDULE 13D, 2026-09-17).
Source of funds (Item 3)
The source of funds used by the reporting person to acquire the securities reported on this Schedule 13D was personal funds. See also Item 4 of this Schedule 13D, which information is incorporated herein by reference.Hamid Khoja, SCHEDULE 13D, 2026-09-17
Purpose of Transaction (Item 4)
Hamid Khoja
On September 15, 2026, the Issuer and the reporting person entered into a securities purchase agreement relating to the issuance and sale of 298,508 shares of the Issuer's common stock and accompanying warrants to purchase up to 298,508 shares of common stock in a private placement. The transaction closed on September 15, 2026. The warrants are exercisable at any time, have an exercise price of $1.55 per share, and expire on the five-year anniversary of the date of issuance. The warrants also contain standard anti-dilution adjustments to the exercise price including for stock splits, stock dividends, rights offerings and pro rata distributions. The Issuer issued the shares and warrants to the reporting person at an offering price of $1.675 per share and accompanying warrant for gross proceeds of approximately $0.5 million. The reporting person made the acquisition described above in support of the Issuer's business plan and for investment purposes. The reporting person may acquire or dispose of additional securities or sell securities of the Issuer from time to time in the market or in private transactions, including as a result of ownership of the warrants referred to above. However, the reporting person does not have any other agreements to acquire additional shares of common stock at this time, except for option agreements governing 102,965 outstanding options granted to the reporting person in the course of his employment with the Issuer. As Chief Scientific Officer of …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 2% | SCHEDULE 13G/A |
| 2026-04-09 | Lind Global Fund III LP | 4.99% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-09-17 | Hamid Khoja | 7.5% | SCHEDULE 13D |
Questions about who owns FibroBiologics, Inc.
Who owns FibroBiologics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of FibroBiologics, Inc.: Armistice Capital, LLC (9.99%, Schedule 13G, filed 2026-08-14) and Hamid Khoja (7.5%, Schedule 13D, filed 2026-09-17).
Who are the largest shareholders of FibroBiologics, Inc.?
By the share each holder's latest filing reports, the largest holders of FibroBiologics, Inc. on this page are Armistice Capital, LLC (9.99%) and Hamid Khoja (7.5%).
When did Armistice Capital, LLC buy into FibroBiologics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G, filed 2026-08-14, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for FibroBiologics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 13, 2026 | Form D, private offering | $1.20M sold | Form D page | Source |
| September 16, 2026 | Form D, private offering | $500K sold | Form D page | Source |
| August 24, 2026 | Leadership change: Leigh Steinberg appointed, Director | — | Leadership changes | Source |
| July 9, 2026 | Leadership change: Kathleen Rubins appointed, Director | — | Leadership changes | Source |
| June 29, 2026 | Form D, private offering | $3M sold | Form D page | Source |
| December 16, 2025 | Form D, private offering | $1.73M sold | Form D page | Source |
| December 3, 2025 | Form D, private offering | $4M sold | Form D page | Source |
| December 3, 2025 | Form D, private offering | $1.50M sold | Form D page | Source |
FibroBiologics, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for FibroBiologics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.